SCHEMBL5216617

SCHEMBL5216617

O=[N+]([O-])c1ccccc1-n1cc(-c2cnc3ccccc3n2)cn1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.53
RAB9A P51151 5/20 0.53
MAPT P10636 10/20 0.53
ADORA3 P0DMS8 1/20 0.47
ALDH1A1 P00352 5/20 0.46
SMN1; SMN2 Q16637 5/20 0.46
LMNA P02545 3/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
HTT P42858 2/20 0.46
NPSR1 Q6W5P4 1/20 0.45
GAA P10253 1/20 0.45
KDM4E B2RXH2 1/20 0.45
HPGD P15428 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.42
HSP90AA1 P07900 1/20 0.42
BCHE P06276 1/20 0.40
PDE3B Q13370 1/20 0.39
PDE3A Q14432 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1206604 0.79 HSP90AA1 (0.52) NPC1RAB9AMAPTALDH1A1SMN1; SMN2
SCHEMBL5215342 0.78 GRM4 (0.57) NPC1RAB9AMAPTALDH1A1SMN1; SMN2
SCHEMBL5217660 0.78 NPC1 (0.51) NPC1RAB9AMAPTADORA3ALDH1A1
SCHEMBL5215941 0.78 NPC1 (0.51) NPC1RAB9AMAPTADORA3ALDH1A1
SCHEMBL8353308 0.78 NPC1 (0.44) NPC1RAB9AMAPTADORA3ALDH1A1
SCHEMBL5220712 0.78 NPC1 (0.44) NPC1RAB9AMAPTADORA3ALDH1A1
SCHEMBL5215644 0.78 NPC1 (0.66) NPC1RAB9AMAPTALDH1A1SMN1; SMN2
SCHEMBL5216583 0.75 NPC1 (0.41) NPC1RAB9AMAPTALDH1A1SMN1; SMN2
SCHEMBL5215183 0.75 NPC1 (0.48) NPC1RAB9AMAPTADORA3ALDH1A1
SCHEMBL5216495 0.74 GRM4 (0.54) NPC1RAB9AMAPTADORA3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458383-B1 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2007-11-21 EP claimed
EP-1458383-A4 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2005-05-25 EP claimed
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME LLC 2005-02-03 US claimed
EP-1458383-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2004-09-22 EP claimed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO claimed
WO-2003051833-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 WO claimed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GRIN2C NPC1 4205/4885RAB9A 1352/4885MAPT 2547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.